Marina Biotech To Show New Research At Cancer Meeting

Marina Biotech (OTCQB:MRNA) will present new data on the use of IT-102 and IT-103 for the treatment of cancer during the American Association for Cancer Research Annual Meeting.
As quoted in the press release:

Dr. Larn Hwang, CSO of Marina Biotech, will present clinical and preclinical studies demonstrating the application of IT-102 and IT-103 in cancer. IT-102 and IT-103 are celecoxib Fixed Dose Combinations (FDCs) combined with lisinopril and olmesartan, respectively, to control the side effects of celecoxib.”
Joseph Ramelli, CEO of Marina Biotech, stated, “These studies lay the foundation for further clinical development of IT-102 and IT-103 for combined hypertensive/pain, as well as for the treatment of cancers such as Familial Adenomatous Polyposis (FAP) and Colorectal Cancer (CRC).”
Dr. Vuong Trieu, Chairman of Marina Biotech and CEO of Autotelic LLC, Marina Biotech’s largest stockholder, stated, “The team deployed an array of technologies to allow safe and effective use of high dose celecoxib, including point of care Therapeutic Drug Monitoring (TDM), exemplifying how personalized dosing will change the administration of medicines from one dose for everyone to the right dose for every patient. We are encouraged by the anticancer activity highlighted in one of these studies, and are excited to further develop IT-102 and IT-103 for the treatment of FAP and CRC.”
Poster Presentations at AACR 2017:
Title: Celecoxib Fixed-dose Combination: Patient Level Data Analyses
Authors: S. Qazi, L. Murphy, A. Mehta, W. Wang, M. Munsif, Z. Yim, V. Trieu
Date and Time: April 3, 2017 at 1:00 pm ET
Title: Celecoxib Fixed-dose Combination: Antitumor Activity on Tumor Growth and Metastasis
Authors: C. Lee, O. J. D’Cruz, K. Ng, V. Trieu
Date and Time: April 4, 2017 at 1:00 pm ET
Title: Celecoxib Fixed-dose Combination: Therapeutic Drug Monitoring
Authors: C. Lee, D. Lee, A. Hu, W. Wang, V. Trieu
Date and Time: April 5, 2017 at 8:00 am ET
About Marina Biotech
Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103 — next generation celecoxib — which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at https://www.marinabio.com.

Click here to read the full press release.

Source: www.marketwired.com